世界の乳房病変誘導システム市場 – 業界動向と2029年までの予測

乳房病変誘導システム市場分析と規模

世界の乳房病変誘導システム市場は、予測期間中に大幅な成長が見込まれています。世界中で毎年診断される乳がんの 3 分の 1 は軽微なものであり、スクリーニング プログラムが普及し、MRI などのより高度なモダリティによって臨床的に潜在的な病変がより多く検出されるようになるにつれて、このレベルは上昇します。これは、乳房画像における疑わしい異常所見を診断するための安全で正確な非外科的方法であり、治療計画を含む適切な意思決定に不可欠です。

データブリッジ市場調査は、2022年から2029年の予測期間における世界の乳房病変誘導システム市場の成長率を分析しています。世界の乳房病変誘導システム市場の予想CAGRは、上記の予測期間中に約5.50％になる傾向があります。市場は2021年に2億5,000万米ドルと評価され、2029年までに3億8,367万米ドルまで成長すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、データブリッジ市場調査チームがまとめた市場レポートには、詳細な専門家分析、患者疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

乳房病変誘導システム市場の範囲とセグメンテーション

市場の定義

心臓CTでは、心臓疾患が見逃されることがよくあります。しかし、マルチディテクタCTの軟部組織機能は、信頼性の高い診断に十分です。乳房病変または損傷は、疾患または損傷によって引き起こされる乳房組織の異常な変化であり、乳房病変の位置を特定する手順は、乳房組織に関連する疾患または損傷を検出、診断、および治療するために使用されます。適切なガイダンスシステムは、市場の成長につながります。

世界の乳房病変誘導システム市場の動向

ドライバー

• 乳がん罹患率の増加

乳がんは、先進国と発展途上国の両方で女性に最も多く見られる病気の一つです。米国がん協会によると、乳がんは世界中の女性のがんによる死亡原因の第 2 位です。世界的に乳がんの症例数は大幅に増加しています。これは主に、ライフスタイルの変化、経口避妊薬の使用増加、豊胸手術などの美容整形手術を受ける女性の増加に起因しています。

•  高齢者人口の増加

年齢を重ねるにつれて、乳がんを発症するリスクは高まります。加齢とともに、多能性前駆細胞（多くの乳がんの原因となる成体幹細胞の一種）が増加し、乳房の乳汁分泌管腔細胞の内側を覆い、腫瘍抑制因子として機能する筋上皮細胞の数が減ります。米国がん協会によると、浸潤性乳がんの約 8 分の 1 は 45 歳未満の女性に発生します。対照的に、浸潤性乳がんの約 3 分の 2 は 55 歳以上の女性に発生します。

機会

• 研究と臨床活動のための資金

さまざまな規制当局や一部の州政府による腫瘍性疾患の治療のための研究開発活動への資金提供の増加も、世界的な臨床開発試験市場の成長を促進すると予想されています。

• 新興経済

Emerging markets such as India, China, Brazil, South Korea, Turkey, Russia and South Africa offer significant growth opportunities for key players operating in the breast lesion guidance market. The large population base of India and China in particular provide a sustainable market for medical and surgical devices as a whole. Emerging market governments are also investing heavily in the development and modernization of healthcare infrastructure. For instance, according to OECD data, China's health care costs in 2020 was $ 810.8 per person. Similarly, Brazil spent about 9.5% of its GDP on health care in 2020, according to health care and financial data. The Brazilian Ministry of Health and several non-governmental agencies have also made efforts to improve early detection in the country and promote breast cancer screening and education.

Restraints/Challenges

• Lack of skilled oncologists

Breast cancer surgery and lesion locating procedures are performed by experienced professionals to achieve better results. These surgeries are considered to be at higher risk than other surgeries due to various challenges such as tumor localization, risk of removal of healthy tissue, lymphedema, and seroma. Similarly, the use of radioactive substances may increase the risk of patients developing radiation-induced cancer. Radiation exposure has several short-term and long-term side effects, usually occurring within 6 months or 1 year of exposure. The most common side effects after radiation exposure include mild pain and discomfort around the breast, skin damage, swelling and inflammation of the breast and surrounding tissues, hair loss on the flanks and breasts, and fatigue. Radiation exposure can also damage nerves in the arms, hands, and chest. To mitigate these risks, the localization procedure requires trained operators and radiologists who must go through a certification process to perform localization of breast lesions.

• Uncertainty in regulatory approval procedures

Regulatory authorities such as the U.S. FDA need comprehensive clinical data to demonstrate the clinical safety and efficacy of approved products. Due to the stringent regulatory requirements for product approval, market players in methods of locating breast lesions (especially radioisotope locating) are nuclear regulated by the Nuclear Regulatory Commission to ensure the safe use of radioactive seeds. You need to get approval for. This approval process is so long and capital intensive that it is difficult for small manufacturers and companies with limited budgets to compete in this market.

This breast lesion guidance systems market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the breast lesion guidance systems market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Breast Lesion Guidance Systems Market

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the forecast period.

The COVID19 pandemic has serious implications for the diagnostic and therapeutic procedures for all non-COVID19 diseases worldwide. This has also impacted the market for breast lesion locating methods, as the adverse effects of COVID19 on people with pandemic-related blockades and comorbidities have significantly reduced attendance at hospitals, clinics and diagnostic centres. In response to COVID 19, many countries have suspended breast screening programs. For instance, in Canada, the Netherlands, Germany, Italy, the United Kingdom and Australia, national screening programs have been completely suspended for one to six months. Therefore, while the market under study was affected by the COVID 19 pandemic, the market under study regains its potential with continued vaccination and a reduction in the number of COVID 19 cases during the forecast period.

Global Breast Lesion Guidance Systems Market Scope

The Global breast lesion guidance systems market is segmented on the basis of type, usage and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Wire
• Radioisotope
• ROLL
• RSL
• Magnetic
• Electromagnetic Localization

Usage

• Breast Biopsy
• Lumpectomy

End-User

• Selection Criteria
• Replacement Trend

Global Breast Lesion Guidance Systems Market Regional Analysis/Insights

The breast lesion guidance systems market is analysed and market size insights and trends are provided by country, type, usage and end-user as referenced above.

The major countries covered in the breast lesion guidance systems market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the breast lesion guidance system market in recent years and is expected to show similar trends over the forecast period due to the high number of breast cancer cases, primarily coupled with strong medical infrastructure and the presence of the breast.

Asia-Pacific region is expected to grow at a significant growth rate during the forecast period of 2022 t0 2029 due to the improving healthcare infrastructure, increasing government funds on breast cancer research, and rapidly rising awareness about the importance of the early detection of breast cancer in several APAC countries.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Breast Lesion Guidance Systems Market Share Analysis

The breast lesion guidance systems market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to breast lesion guidance systems market.

Key players operating in the breast lesion guidance systems market include:

• BD (US)
• C.R. Bard, Inc. (US)
• Devicor Medical Products Inc. (US)
• Hologic Inc. (US)
• Merit Medical Systems (US)
• Leica Biosystems Nussloch GmbH (US)
• Argon Medical Devices (US)
• Laurane Medical LLC (France)
• Endomagnetics Ltd. (UK)
• Intramedical Imaging, LLC (US)
• Isoaid (US)
• Surgiceye GmbH (Germany)
• Ranfac Corp. (US)
• Mermaid Medical Group (Denmark)
• Izi Medical Products, LLC (US)
• Matek Medikal (Turkey)
• Tsunami Medical Srl (Italy)
• BPB Medica (Italy)
• Sirius Medical Systems B.V. (Netherlands)
• Molli Surgical Inc. (Canada)
• Sterylab S.R.L. (Italy)
• CP Medical (Georgia)
• MDL SRL (Italy)
• Biomedical Srl (Italy)
• Elucent Medical (US)
• Vigeo srl（イタリア）
• Medax Medical Devices（イタリア）

SKU-68833